Pri-Med Irving | Regional CME/CE Conference

Description

Timely detection of mild cognitive impairment (MCI) due to Alzheimer disease (AD) is an integral step to improving patient outcomes. This insightful session discusses early identification of MCI, clinical evaluation for an AD diagnosis, and new and emerging therapies. Gain valuable strategies to elevate detection and treatment of AD in your practice.

The session: Alzheimer Disease in Primary Care: Early Identification and New Anti-Amyloid Treatment Options (1 hour) is designed to satisfy CE state licensure requirements in Texas (NP) on Older Adult or Geriatric Populations and is also approved for Ethics and Professional Responsibility CME Credit in Texas (MD/DO).

Learning Objectives

• Incorporate strategies that promote the early detection of mild cognitive impairment (MCI) due to Alzheimer disease (AD) into routine primary care practice
• Discuss the clinical evaluation involved in diagnosing AD, with consideration of the expanding role of biomarkers
• Examine the evidence supporting new and emerging anti-amyloid therapies, including which patient populations derive the greatest therapeutic benefit